BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/23/2025 8:03:21 AM | Browse: 5 | Download: 15
 |
Received |
|
2025-05-12 02:38 |
|
Peer-Review Started |
|
2025-05-13 00:03 |
|
First Decision by Editorial Office Director |
|
2025-05-30 02:49 |
|
Return for Revision |
|
2025-05-30 02:49 |
|
Revised |
|
2025-06-23 00:42 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-09-26 02:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-09-26 08:49 |
|
Articles in Press |
|
2025-09-26 08:49 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-12-15 08:30 |
|
Publish the Manuscript Online |
|
2025-12-23 08:03 |
| ISSN |
2220-6124 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Minireviews |
| Article Title |
Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Harry Economos and Richard J MacIsaac |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Richard J MacIsaac, Director, Professor, Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, 4th Floor, Daly Wing, 35 Victoria Parade, PO Box 2900, Fitzroy 3065, Victoria, Australia. r.macisaac@unimelb.edu.au |
| Key Words |
Albuminuria; Diabetes; Chronic kidney disease; Glucagon-like peptide-1 receptor agonist; Semaglutide |
| Core Tip |
In people with type 2 diabetes and chronic kidney disease, semaglutide, saves kidneys, hearts and lives. The glucagon-like peptide-1 receptor agonist (GLP-1RA) class of medications are now being proposed as the fourth pillar of diabetic kidney disease therapy, along with renin-angiotensin-aldosterone system blocking agents, sodium glucose co-transporter-2 inhibitors, and finerenone. We await definitive evidence to support a kidney protective effect of GLP-1RAs outside of the setting of diabetes. |
| Publish Date |
2025-12-23 08:03 |
| Citation |
Economos H, MacIsaac RJ. Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease. World J Nephrol 2025; 14(4): 109457 |
| URL |
https://www.wjgnet.com/2220-6124/full/v14/i4/109457.htm |
| DOI |
https://dx.doi.org/10.5527/wjn.v14.i4.109457 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
